The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia

by Sara Samadzadeh, Raphaela Brauns, Harald Hefter
Published 2021-12-01

Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy

by Harald Hefter, Isabelle Schomaecker, Max Schomaecker, Sara Samadzadeh
Published 2020-11-01

Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia

by Harald Hefter, Dietmar Rosenthal, Hans Bigalke, Marek Moll
Published 2019-12-01

The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia

by Harald Hefter, Isabelle Schomaecker, Max Schomaecker, Dietmar Rosenthal, Sara Samadzadeh
Published 2021-07-01

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins

by Harald Hefter, Christian J. Hartmann, Ulrike Kahlen, Sara Samadzadeh, Dietmar Rosenthal, Marek Moll
Published 2021-02-01

The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany

by Sara Samadzadeh, Raphaela Brauns, Dietmar Rosenthal, Harald Hefter
Published 2021-01-01

Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA

by Harald Hefter, Sara Samadzadeh, Marek Moll
Published 2020-10-01

Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature

by Sara Samadzadeh, Beyza Ürer, Raphaela Brauns, Dietmar Rosenthal, John-Ih Lee, Philipp Albrecht, Harald Hefter
Published 2020-08-01

Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson’s Disease: Six Cases and Literature Review

by Harald Hefter, Sara Samadzadeh
Published 2021-03-01